| 2001-2003 |
Bologna Fabrina
|
University of La Plata Faculty of Medicine
La Plata, Argentina |
Istituto Nazionale dei Tumori
Milan, Italy |
Correlation between
tumor markers and response to systemic doxorubicin/paclitaxel
neoadjuvant chemotherapy in patients with locally advanced
breast cancer |
ESMO |
| 2001-2003 |
Kulimova Emma
|
National Hematology Research Centre Moscow, Russian
Fed. |
Medizinische Klinik &Poliklinik Innere Medizin
Münster, Germany |
Tissue inhibitor of metallo-proteinases
1 (TIMP-1) is an autocrine/paracrine survival factor with
additional immune-regulatory functions expressed by Hodgkin-Reed/Sternberg
(H‑R/S) cells |
ESMO |
| 2002-2003 |
Bellova Veronika
|
NCI
Dept of Internal Medicine
Bratislava, Slovak Rep. |
Universitätsklinikum Köln
Klinik I für Innere Medizin
Köln, Germany |
1. APVG – a regimen for first line treatment of elderly
patients with Hodgkin's disease
2. The development of new immunotherapeutic approaches for
patients with Hodgkin's disease |
ESMO |
| 2002-2003 |
Galani Eleni |
Alexandra Hospital
Dept of Clinical Therapeutics
Athens, Greece |
Guy's & St. Thomas Hospital
St. Thomas Street
London, United Kingdom |
Detection of specific
T-cells in the peripheral blood and in the bone marrow of
patients with early breast cancer recognizing epitopes from
Tumor Antigens |
ESMO |
| 2002-2003 |
Michalaki Vasiliki |
University of Athens Oncology Unit
3rd Dept of Medicine
Athens, Greece |
Royal Marsden Hospital
NHS Trust
London, United Kingdom |
Novel gene therapy approaches (prodrug enzyme therapy)
in patients with locally advanced and/or relapsed head and
neck cancer |
ESMO
|
| 2002-2003 |
Teterin Alexei |
Novosibirsk Regional
Diagnostic Centre
Novosibirsk, Russian Federation |
University Clinic of Vienna
Dept of Oncology
Vienna, Austria |
Isolation of tumor DNA/RNA from the sera of patients
with prostate carcinoma |
ESMO |
| 2002-2003 |
Vera Karina |
Hospital Britanico Medical Oncology
Buenos Aires, Argentina |
Institut Gustave Roussy
Medical Phase I Unit
Villejuif, France |
Phase I ascending dose study of intravenous ES-285 in
patients with advanced malignant solid tumors |
ESMO |
| 2003-2004 |
Vischioni Barbara |
Ospedale Luigi Sacco
Milan, Italy |
Free University Hospital
Dept of Med Oncology
1117 De Boelelaan
Amsterdam, Netherlands |
Nuclear-cytoplasmic localization
of IAPs as novel marker for tumor progression |
ESMO
|
| 2003-2004 |
Wannesson De Nicola Luciano |
Fundaleu
Buenos Aires, Argentina |
Oncology Institute of Southern
Switzerland
Ospedale S Giovanni
Bellinzona, Switzerland |
Development of analogs in solid tumors an oral camptothecin
in non small cell lung cancer NSCLC |
ESMO |
| 2003-2004 |
Godal Robert |
National Cancer Inst.
Dept. Internal Medicine Bratislava, Slovak Rep. |
FU Berlin
Medizinische Klinik III
Berlin, Germany |
Regulation of WT1 expression in human solid tumors and
presentation to the immune system |
ESMO |
| 2003-2004 |
Joerger Markus |
Kantonsspital St. Gallen Dept Innere Medizin
St. Gallen Switzerland |
The Netherlands Cancer Inst.
A. van Leeuwenhoek Hospital
Div of Medicine
Amsterdam, Netherlands |
Pharmacogenotyping and –phenotyping in cancer patients
to explore associations with anticancer drug pharmacokinetics
and toxicity |
ESMO |
| 2003-2004 |
Besse Benjamin |
Institut Gustave Roussy
Dept of Medicine
Villejuif, France |
Institut Català d'Oncologia
Medical Oncology Dept
Badalona, Spain |
Research on genetic assessment of chemotherapy response |
ESMO |
| 2004-2005 |
Palma Marzia |
Medical Oncology,
La Sapienza Univerity
Rome, italy
|
Cancer Centre Karolinska Radiumhemmet
Dept of Oncology
Stockholm, Sweden |
Leukemia specific T cells in
chronic lymphocitic leukemia and the development of a leukemia
specific vaccination approach |
ESMO |
| 2004-2005 |
Martinelli Erika |
University of
Naples
Naples, Italy |
Vall d'Hebron
University Hospital
Barcelona, Spain |
To investigate the effects of
the mTOR inhibitor everolimus (RAD001) in patients with advanced
solid tumours |
Ortho Biotech
|
| 2004-2005 |
Godal Robert |
National Cancer
Institute
Bratislava, Slovakia |
Charite Campus
Berlin, Germany |
Regulation of WT1 expression
in human solid tumors and presentation to the immune system
|
Amgen |
| 2004-2005 |
Akimov Mikhail
|
N.N. Petrov Research
Inst. of Oncology
St. Petersburg,
Russia |
Krankenhaus Nordwest
Frankfurt, Germany
|
Expression and Immunogenicity
of the Tumor Associated Antigens in Lung Cancer Patients |
Merck |
| 2004-2005 |
Neciosup Delgado Silvia |
Instituto
de Enfermedades Neoplasicas
Lima, Peru |
Hospital
Universitario 12 de Octubre
Madrid,
Spain |
Phase I clinical, pharmacokinetic
and biological trial with escalating doses of the PPARg ligand
Pioglitazone in patients with advanced solid tumors
|
AstraZeneca |
| 2005 |
Conforti Rosa |
Ospedale Bellaria
Bologna, italy |
Institut Gustave
Roussy
Villejuf Cedex,
France |
Predictive factors for the benefit
of adjuvant chemotherapy in breast cancer patients: A biomarker
project |
ESMO |
| 2005-2006 |
Bradic Maja |
Institute
of Oncology
Sremsak Kamenica
Sremska
Kamenica , Serbia and Montenegro
|
Cancer
Center
Karolinska
Stockholm, Sweden |
Development of PDGF receptors
as clinical cancer drug targets |
Amgen |
| 2005-2006 |
Aydin Semra |
University Hospital
Essen
Essen, Germany |
University of
Turin
Turin, Italy |
CD 38 signaling in B-cell chronic
lymphocytic leukaemia (B-CLL) |
AstraZeneca |
| 2005-2006 |
Mountzios Ioannis |
251 Airforce General
Hospital
Athens, Greece |
Institute Gustave
Roussy
Villeiuf Cedex,
France |
Study of interactive activation
of melecolar Signalling pathways in non-small cell lung cancer
(NSCLC) in relation to histological and clinical features
|
ESMO |
| 2005-2006 |
Palma Marzia |
Medical Oncology, La Sapienza University,
Rome, Italy |
Cancer Centre
Karolinska, Radiumhemmet
Stockholm, Serden |
Leukemia specific T cells in
chronic lymphocitic leukaemia and the development of a leukaemia
specific vaccination approach |
Ortho Biotech
|
| 2006-2007 | Atzori Francesco
| University of Cagliari,
Cagliari Italy | Vall d'Hebron University Hospital, Barcelona, Spain
| A phase III randomized, controlled trial of myocet, trastuzumab and paclitaxel versus trastuzumab and paclitaxel for first line therapy of metastitic breast cancer
| Amgen |
| 2006-2007 | Koychev Daniel
| Medical University of Plovdiv, Plovdiv, Bulgaria
| Charité Campus Benjamin Franklin Berlin, Germany | The role of Pax genes for regulation of the Wilm's tumor gene 1 (WT1) in carcicoma cells and tumor cell proliferation
| Amgen |
| 2006-2007 | Wermann Hendrik
| Universitätsklinikum Hamburg-Eppendorf Hamburg, Germany
| Erasmus Medical Center Rotterdam, The Netherlands | The role of microsatellite instability and BRAF mutations in chemotherapy resistance of germ cells tumors
| Novartis |
| 2006-2007 | Lyros Orestis
| University of Athens Medical School, Athens Greece | Mainz University Clinic,
Mainz Germany | Molecular markers of tyrosine kinase signaling receptor pathways for clinical prognosis and prediction under TKI therapy in human gastrointestinal in vivo and in vitro
| AstraZeneca |
| 2006-2007 | Olmos Hidalgo David
| Hospital Clinico Universitario de Malaga,
Malaga, Spain | Royal Marsden Hospital, Sutton, UK
| Utilizing circulating tumor cells to identify molecular targets and to optimize drug selection and treatment in patients with hormone refractory prostate cancer | Bayer Oncology |
| 2006-2007 | Ruiz Soto Rodrigo
| Instituto Nacional de Cancerologia
Mexico City, Mexico | Institut Gustave Roussy, Villejuif, France
| Search for predictive biomarkers of response to induction chemotherapy API-AI (doxorubicin, ifosfamide and cisplatine) in patients with locally advanced soft tissue sarcoma
| Wyeth Pharmaceuticals
|
| 2007-2008 | Celebic Aleksandar
| Institute of Oncology and Radiology of Serbia.
Belgrade, Serbia
| Institut Gustave Roussy,
Villejuif France | Multiple gene expression deregulation during the benign-malignant transition in the breast: diagnostic and prognostic value
| Amgen |
| 2007-2008 | Opitz Isabelle
| Division of Thoracic Surgery, University Hospital Zurich
Zurich, Switzerland
| Clinic and Policlinic for Oncology, University Hospital Zurich
Zurich, Switzerland
| Intrapleural therapy after surgery for malignant pleural mesothelioma
| Bayer Oncology
|
| 2007-2008 | Cresti Nicola
| Medical Oncology Division, St. Chiara University Hospital, Pisa, Italy | Northern Institute for Cancer Research, University of Newcastle upon Tyne,
Newcastle, UK | Pharmacogenetic study of FcyRlllA and HER2 genes in relation to treatment of breast cancer
| Amgen |
| 2007-2008 | Loi Sherene
| Department of Medical Oncology & Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australia
| Jules Bordet Institute,
Brussels, Belgium | Understanding the molecular heterogeneity of response and resistance to anti-HER2/ErbB2 agents in breast cancer
| Novartis |
| 2007-2008 | Markman Ben
| Medical Oncology Department, Vall d'Hebron University Hospital,
Barcelona, Spain | Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain | Effects of Pl3K Pathway Inhibition and Biomarker Development
| Wyeth Pharmaceuticals
|
| 2007-2008 | Zoubir Mustapha
| Centre Hospitalo-Universitaire d'Oran,
Oran, Algerie | Institut Gustave Roussy,
Villejuif France | Novel subset of regulatory immune cell: characterization of inhibitory NKalb
| GE Healthcare
|
